Effect of add-on Doxofylline on Lung Function in Stable COPD
Status:
Not yet recruiting
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
It is a phase IV, prospective, interventional, single blind, randomized, crossover trial in
which the investigators will evaluate the effects of a 4-week treatment with doxofylline 400
mg bid, in add-on to maximal inhalation therapy, in clinically stable COPD patients.